Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUNIPER: JADE101 in IgA Nephropathy
NCT07541287Phase 2Recruiting
- Sponsor
- Jade Biosciences, Inc.
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of JADE101 in IgA nephropathy (IgAN), sponsored by Jade Biosciences, Inc.. Started May 2026; status: recruiting.
02
Drugs
JADE101
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07541287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541287.